Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors

Memorias do Instituto Oswaldo Cruz

Volumn 108, Issue 1, 2013, Pages 13-17

  Bonome Zeminian, Luciana ^a   Lara Padovani, Juliana ^a   Maria Corvino, Sílvia ^a   Faria Silva, Giovanni ^b   Pardini, Maria Inês de Moura Campos ^a,b   Tommasini Grotto, Rejane Maria ^a  

^a Laboratório de Biologia Molecular   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

HCV genotype 1a; NS3 protease mutations; Protease inhibitors

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; NS3 PROTEIN, HEPATITIS C VIRUS; RIBAVIRIN; VIRUS PROTEIN; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MIDDLE AGED; MUTATION; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RIBAVIRIN; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84875454492     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762013000100002     Document Type: Article

References (32)

1. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naïve subjects. J Infect Dis 198: 800-807.
2. Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, Gérolami R 2008. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment- naïve chronically infected patient. Hepatology 47: 766-767.
3. Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, Esteban R, Guardia J, Quer J 2008. Naturally occuring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370: 237-245.
4. de Carvalho-Mello IMVG, Medeiros Filho JE, Gomes-Gouvêa MS, Malta F de M, De Queiróz ATL, Pinho JRR, Carrilho FJ 2010. Molecular evidence of horizontal transmission of hepatitis C virus within couples. J Gen Virol 91: 691-696.
5. de Francesco R, Carfi A 2007. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 59: 1242-1262.
6. Ewing B, Green P 1998. Base-calling of automated sequencer traces using Phred. II. Error probabilities. Genome Res 8: 175-194.
7. Ewing B, Hillier La Deana, Wendl MC, Green P 1998. Base-calling of automated sequencer traces using Phred. I. Accuracy assessment. Genome Res 8: 175-185.
8. FDA - Food and Drug Administration 2011. [homepage on the internet]. Hepatitis C experts sought for FDA Advisory Committee. Available from: hivandhepatitis.com/help_c/news/2010/1210_2010_a.html, 2010.
9. Hahm B, Han DS, Back SH, Song OK, Cho MJ, Kim CJ, Shimotohno K, Jang SK 1995. NS3-4A of hepatitis C virus is a chymotrypsin-like protease. J Virol 69: 2534-2539.
10. Halfon P, Locarnini S 2011. Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192-206.
11. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CCJ, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG 2006. Treatment for adult HIV infection: 2006 recommendations of the international AIDS society - USA panel. JAMA 296: 827-843.
12. Higgens DG, Thompson JD, Gibson TJ 1996. Using CLUSTAL for multiple sequence alignments. Methods Enzymol 266: 383-402.
13. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S 2007. Telaprevir ad pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46: 631-639.
14. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87: 343-355.
15. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur, Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48: 1769-1778.
16. Love RA, Parge HE, Wickesham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87: 331-342.
17. Lu L, Dekhtyar T, Masse S, Pithawalla R, Krishnan P, He W, Ng T, Koev G, Stewart K, Larson D, Bosse T, Wagner R, Pilot-Matias T, Mo H, Molla A 2007. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Res 76: 93-97.
18. Malet I, Belnard M, Agut H, Cahour A 2003. From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. J Virol Methods 109: 161-170.
19. McHutchison JG, Everson GT, Gordon S, Jacobson I, Kauffman R, McNair L, Muir AJ 2007. Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon-alfa-2a and ribavirin in previously untreated subjects with hepatitis C. Annual meeting of the European association for the study of the liver. J Hepatol 46 (Suppl. 1): S296.
20. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM 2004. Structural biology of hepatitis C virus. Hepatology 39: 5-19.
21. Peres-da-Silva A, de Almeida AJ, Lampe E 2010. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients. Arch Virol 155: 807-811.
22. Qiu P, Sanfiorenzo V, Curry S, Guo Z, Liu S, Skelton A, Xia E, Cullen C, Ralston R, Greene J, Tong X 2009. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 37: e34.
23. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu H-M, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 137: 1767-1777.
24. Susser S, Welker M, Zettler M, Wohnsland A, Hughes E, Ralston R, Tong X, Zeuzem S, Sarrazin C 2008. Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir (SCH503034). J Hepatol 48 (Suppl. 2): S29.
25. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50: 1709-1718.
26. Thompson AJV, McHuntchison JG 2009. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Virol Hepat 16: 377-387.
27. Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, Ralston R 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 77: 177-185.
28. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH503034. Antiviral Res 70: 28-38.
29. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien C, Goudeau A, Picard B 2005. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol 75: 528-537.
30. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J 2004. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2. J Hepatol 40: 993-999.
31. Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Forestier N, Gupta S, Deckman D, Fellows K, Hussain M, Cutler D, Zhang J 2005a. Anti-viral activity of SCH 503034, a HCV protease inhibitor administered as monotherapy in HCV-1 patients refractory to pegylated interferon (PEG-INF-α). Hepatology 42: 233A-234A.
32. Zeuzem S, Sarrazin C, Wagner F, Rouzier R, Forestier N, Gupta S, Hussain M, Shah A, Cutler D, Zhang J 2005b. Combination therapy with HCV protease inhibitor SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders: phase 1b results. Hepatology 42: 276A-277A.